Top 10 Korean Pharma Companies
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Address: 711, Royal Bldg 5 Dangju-dong, Jongro-gu, Seoul,Republic of Korea
Tel: +82 2 730 1451
Web: http://www.admRepublic of Korea.co.kr/
ADM Inc. is leader in providing full clinical services in Republic of Korea. ADM is a member of EPS group (HQ is located in Tokyo, www.eps.co.jp / www.eps-inter.com). If you consider Asian multi-national clinical study, ADM together with EPS will be the best choice.
Some of the services that we excell on providing are: Regulatory Strategy Consulting Registration Dossier IND Submission Communication with Regulatory Authorities Regulatory Change Reporting Phase I-IV Clinical Trial Project Planning Protocol and CRF Development Investigator Recruitment and Site Selection IRB Submission Investigational Staff Training Clinical Trial Management Monitoring Quality Control Quality Assurance Data Management Statistical Analysis Clinical Trial Report Writing Protocol & CRF Development IRB Submission Investigational Staff Training Project Management Data Collection and Monitoring Data Entry Data Management Statistical Analysis Safety Report Annual and Final Report Writing Data Management Plan Development Customized Database Design & Development Verification and Edits Medical Coding By MedDRA, WHO-ART, KIMs, Etc. Double Data Entry Full Electronic Audit Trail Data Comparison Query Generation and Resolution Data Transfer and Management Statistical Analysis Plan Development Statistical Programming and Validation Statistical Reports Statistical Consulting Project Master Files/ Essential Documents Audits Investigator Site Audits Sponsor Audits System Audits Pre-regulatory Inspection Audits, Including Preparation and Training for the Inspection Protocol Translation Informed Consent Form Translation Clinical Trial Report Translation IB Translation IRB Submission Document Translation All of Clinical Trial Document Translation
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other oncology products. He also discusses the potential and…
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
See our Cookie Privacy Policy Here
